相关实验视频

Updated: Jun 29, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

刺痛激动剂会引起宫癌免疫微环境的炎症,并克服抗PD-1疗法耐药性

Tianye Li¹, Weijiang Zhang¹, Mengke Niu²

¹Department of Gynecology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.

Frontiers in immunology

|March 29, 2024

概括

像MSA-2这样的刺痛激动剂通过增强抗瘤免疫力来增强宫癌的潜力. 将MSA-2与免疫检查点抑制剂结合起来,有效地抑制了瘤生长,并在临床前模型中改善了结果.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
基因组学就是基因组学.

背景情况:

宫癌带来了重大挑战,特别是在晚期.
目前的治疗方法由于免疫抑制瘤微环境而存在局限性.
刺痛激动剂为宫癌提供了一种新的治疗途径.

研究的目的:

研究STING通路下游基因在宫癌预后中的作用.
评估MSA-2的治疗潜力,一种STING激动剂,在宫癌中.
评估MSA-2对瘤免疫微环境的影响及其与抗PD-1治疗的联合疗效.

主要方法:

对STING下游基因表达的TCGA和GEO数据集的分析和与临床病理学数据的相关性.
使用ESTIMATE和deconvo_CIBERSOR进行免疫透分析.
scRNA-seq和in vivo小鼠模型来评估MSA-2的疗效及其对瘤微环境的影响.

主要成果:

升高的STING下游基因表达与更好的宫癌预后和增加的免疫透相关.
MSA-2在瘤微环境中表现出免疫启动和激活功能.
单独或与抗PD-1结合的MSA-2抑制了瘤生长,组合疗法显示出更高的疗效.

结论:

在宫癌免疫力中,STING通路起着至关重要的作用.
MSA-2显示出重塑宫癌免疫微环境的巨大潜力.
使用MSA-2和免疫检查点抑制剂的联合治疗为改善患者预后提供了一个有希望的策略.

关键词:

刺痛激动剂刺痛激动剂对抗PD-1的治疗方法.宫癌:子宫癌是一种癌症.一个单细胞RNA-seqq.瘤微环境是一个微环境.

更多相关视频

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...